Addex Therapeutics Ltd. Sponsored ADR ADXN
3.65
0.19
5.49%
as of 25 Sep
- Market cap
- $3.6M
- P/E
- 0.0×
Follow ADXN
Growth Flags
show if company had growth for consecutive years
| Older periods | Jun '25 | Sep '25 | Dec '25 | Mar '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(57.77%) | (66.93%) | (96.99%) | (129.15%) | |
| (51.59%) | (58.31%) | (81.98%) | (104.27%) | ||
ROIC |
(29.36%) | (39.10%) | (56.24%) | (69.46%) | |
Return on Tangible Assets |
(359.22%) | (455.03%) | (1,396.34%) | 21,295.09% | |
Average Days of Receivables |
0.00 | 101.88 | 87.63 | 0.00 | |
Free Cash Flow per Share |
(2.22) | (1.98) | (2.93) | (2.97) | |
Free Cash Flow |
(1.86) | (1.86) | (2.62) | (2.93) | |
Piotroski F-Score |
— | 3.00 | 1.00 | — | |
| Other line items | |||||
Cash ROIC |
(16.16%) | (18.28%) | (33.90%) | (54.42%) | |
Accounts Receivable Turnover |
0.00 | 0.74 | 4.82 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 358.40% | 804.27% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 1,009.07% | 2,773.02% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 43.70% | 84.82% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.28 | 0.27 | 0.32 | 0.34 | |
Depreciation/Fixed assets |
89.55 | 30.30 | 11.33 | 25.38 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.24 | 0.11 | 0.00 | |
Operating CF per Share |
(2.22) | (1.98) | (2.93) | (2.97) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | — | |
Net Profit Margin |
0.00% | (2,952.25%) | (8,056.65%) | 0.00% |
Columns are period end dates